As nicotine products continue to evolve, regulators and researchers face a recurring challenge: how can the performance of new products be evaluated efficiently, accurately, and consistently without relying exclusively on costly and time-consuming human clinical studies?
A newly published study in Scientific Reports offers an interesting contribution to that discussion. Rather than focusing on consumer behaviour or public health outcomes, the research examines a more technical but increasingly important question: can scientists accurately predict how nicotine pouches will deliver nicotine in the human body using laboratory-based testing methods?
The findings may have implications not only for product development but also for how regulators evaluate emerging nicotine products in the future.
Understanding Nicotine Pharmacokinetics
When discussing nicotine products, one of the most important scientific concepts is pharmacokinetics (PK), the study of how a substance is absorbed, distributed, metabolised, and eliminated by the body.
For nicotine products, pharmacokinetic measurements help researchers understand how quickly nicotine is delivered, how much nicotine enters the bloodstream, and how long nicotine remains available to the user.
These factors influence product performance, user experience, and, potentially, the extent to which products may substitute for combustible cigarettes.
Traditionally, pharmacokinetic assessments rely on human clinical studies. While these studies remain the gold standard, they are often expensive, resource-intensive, and time-consuming.
Researchers have therefore been exploring whether laboratory models can provide reliable predictions before clinical testing takes place.
The New Predictive Model
The study, Development of a Model to Predict Nicotine Pharmacokinetics from Oral Nicotine Pouches, was published in Scientific Reports in 2026 by M.M. Knopp and colleagues. The researchers developed a predictive model designed to estimate nicotine absorption from oral nicotine pouches using laboratory-generated data rather than relying solely on clinical trials.
To test the model, researchers examined several commercially available nicotine pouch products and generated data on nicotine dissolution and pH levels under controlled laboratory conditions. These findings were then combined with established pharmacokinetic parameters to predict clinical nicotine absorption outcomes.
The results showed that the model was able to accurately forecast key pharmacokinetic measurements, including nicotine exposure over time (AUC), peak nicotine concentration (Cmax), and time to peak concentration (Tmax).
While further validation is likely to be required, the study demonstrates that laboratory testing may be capable of providing meaningful insights into product performance before human studies are conducted.
Why pH Matters
One of the most notable findings was the role played by pH.
The researchers found that buccal and saliva pH can significantly influence nicotine absorption. Small differences in product formulation can affect how much nicotine is available in a form that can pass through the oral mucosa and enter the bloodstream.
This finding highlights an important point often overlooked in policy discussions.
Nicotine content alone does not necessarily determine how a product performs. Two products with similar nicotine concentrations may produce different nicotine delivery profiles depending on formulation characteristics, pH, moisture content, and other design factors.
For regulators, this raises questions about whether product standards should focus solely on nicotine content or whether broader performance characteristics may also warrant consideration.
Implications for Regulatory Science
The study’s significance lies less in the specific products tested and more in the methodology itself.
Across multiple industries, regulators increasingly rely on predictive modelling and laboratory-based assessments to support decision-making. Pharmaceutical regulation, medical device assessment, and chemical safety evaluation all make extensive use of validated predictive tools.
The nicotine sector may be moving in a similar direction.
If predictive models can reliably estimate nicotine delivery characteristics, they could potentially support product assessments, facilitate scientific review, and improve understanding of product performance without replacing the need for clinical research.
Importantly, this does not mean laboratory models should substitute entirely for human evidence. Real-world behaviour, consumer preferences, long-term health outcomes, and population-level impacts still require clinical and epidemiological investigation.
However, predictive tools may help improve efficiency and generate valuable evidence earlier in the product evaluation process.
A Broader Trend in Nicotine Research
The study also reflects a broader shift occurring within nicotine science.
As product categories diversify, researchers are increasingly focused not only on whether products contain nicotine, but also on how nicotine is delivered, absorbed, and used.
Questions surrounding nicotine pharmacokinetics have become particularly relevant as regulators evaluate nicotine pouches, synthetic nicotine products, and other emerging nicotine technologies.
Understanding these mechanisms may ultimately contribute to more sophisticated regulatory frameworks that move beyond simple product categorisation and toward evidence-based assessments of product characteristics and performance.
Looking Ahead
The development of predictive pharmacokinetic models represents an important area of scientific innovation within nicotine research.
While such models are unlikely to replace clinical studies, they may offer researchers and regulators an additional tool for evaluating product design, understanding nicotine delivery, and supporting evidence generation.
As nicotine regulation continues to evolve, scientific advances of this kind may help improve the quality of regulatory decision-making while reducing the time and resources required to assess emerging products.
For policymakers, the key lesson is not about any specific brand or manufacturer. Rather, it is that modern nicotine governance increasingly depends on robust scientific methodologies capable of keeping pace with innovation.
As new nicotine products continue to emerge, the ability to predict, measure, and understand product performance may become just as important as the products themselves.
Source:
Knopp MM et al., Development of a Model to Predict Nicotine Pharmacokinetics from Oral Nicotine Pouches, Scientific Reports (2026).
